Literature DB >> 16379516

Performance of clinician versus self-report measures to identify obsessive-compulsive disorder in children and adolescents.

S Evelyn Stewart1, T Atilla Ceranoglu, Tara O'Hanley, Daniel A Geller.   

Abstract

OBJECTIVE: The aim of this study was to study agreement between clinician-rated measures and self-report measures previously used in epidemiologic studies to identify obsessive-compulsive disorder (OCD) in youth and to determine the adequacy of self-report measures as screening instruments.
METHOD: Leyton Obsessional Inventory-Child Version (LOI-CV) survey form self-report and Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) clinician-report measures were compared in a sample of 81 OCD-affected youths diagnosed using structured diagnostic interviews and the best-estimate method. Sensitivities and agreement between tests are determined for different cutoff scores.
RESULTS: The LOI-CV survey form total (item+interference) score is correlated with KSADS-E OCD severity (r=0.37, p=0.001) but not clinician-rated GAF scores (r=-0.18, p=0.12). LOI-CV survey form sensitivities at cutoff scores of 15, 20, 25, and 30 are 55%, 36%, 28%, and 19%, respectively. CY-BOCS scores are correlated with subject-rated interview severity (p<0.001) and clinician-rated GAF scores (p<or=0.05). CY-BOCS sensitivities at cutoff scores of 8, 10, 12, and 14 are 100%, 99%, 98%, and 90%. The cutoff scores required for greater than 95% sensitivity of the LOI-CV survey form and the CY-BOCS, respectively, are 2 and 12. LOI-CV survey form total scores do not correlate with CY-BOCS total or obsession subscores (p>or=0.03), but correlate with the CY-BOCS compulsion subscore.
CONCLUSIONS: The clinician-rated CY-BOCS measure using parent and child reporting performs superiorly to the subject-rated LOI-CV measure using child reporting to identify pediatric OCD in a clinically referred population. Because self-report measures have been used in epidemiological studies, youth OCD prevalence rates may be higher than previously reported.

Entities:  

Mesh:

Year:  2005        PMID: 16379516     DOI: 10.1089/cap.2005.15.956

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  6 in total

1.  The Leyton Obsessional Inventory-Child Version Survey Form does not demonstrate adequate psychometric properties in American youth with pediatric obsessive-compulsive disorder.

Authors:  Eric A Storch; Jennifer M Park; Adam B Lewin; Jessica R Morgan; Anna M Jones; Tanya K Murphy
Journal:  J Anxiety Disord       Date:  2011-02-02

2.  Psychometric properties of the Children's Yale-Brown Obsessive Compulsive Scale in youth with autism spectrum disorders and obsessive-compulsive symptoms.

Authors:  Monica S Wu; Joseph F McGuire; Elysse B Arnold; Adam B Lewin; Tanya K Murphy; Eric A Storch
Journal:  Child Psychiatry Hum Dev       Date:  2014

3.  European clinical guidelines for Tourette syndrome and other tic disorders. Part I: assessment.

Authors:  Danielle C Cath; Tammy Hedderly; Andrea G Ludolph; Jeremy S Stern; Tara Murphy; Andreas Hartmann; Virginie Czernecki; Mary May Robertson; Davide Martino; A Munchau; R Rizzo
Journal:  Eur Child Adolesc Psychiatry       Date:  2011-04       Impact factor: 4.785

4.  Children's Florida Obsessive Compulsive Inventory: psychometric properties and feasibility of a self-report measure of obsessive-compulsive symptoms in youth.

Authors:  Eric A Storch; Muniya Khanna; Lisa J Merlo; Benjamin A Loew; Martin Franklin; Jeannette M Reid; Wayne K Goodman; Tanya K Murphy
Journal:  Child Psychiatry Hum Dev       Date:  2009-03-27

5.  Assessment and medication management of paediatric obsessive-compulsive disorder.

Authors:  S Evelyn Stewart; Dianne Hezel; Andrea C Stachon
Journal:  Drugs       Date:  2012-05-07       Impact factor: 9.546

6.  A study of sensory dysregulation in children with tic disorders.

Authors:  Hana Weisman; Shula Parush; Alan Apter; Silvana Fennig; Noa Benaroya-Milshtein; Tamar Steinberg
Journal:  J Neural Transm (Vienna)       Date:  2018-02-23       Impact factor: 3.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.